Stockscreener 앱 받기
1.91
6.83%
-0.14
시간 외 거래:
1.88
-0.03
-1.57%
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - FinancialContent
MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada
Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com
MAIA Biotechnology secures $1.08 million in private placement - Investing.com
MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan
MAIA Biotechnology Announces $1.08 Million Private Placement - Yahoo Finance
MAIA Biotechnology Inc (MAIA) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Do investors need to be concerned about MAIA Biotechnology Inc (MAIA)? - uspostnews.com
MAIA Biotechnology Inc: Navigating Market Fluctuations with a 60.66M Market Cap - investchronicle.com
MAIA Biotechnology Inc [MAIA] stock for 50,000 USD was acquired by Guerrero Ramiro - knoxdaily.com
MAIA’s Q2 earnings predictions: What the experts say - uspostnews.com
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 14.8% – Here’s Why - Defense World
MAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimer - MSN
MAIA stock touches 52-week low at $1.41 amid market challenges - Investing.com India
MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval - MarketScreener
MAIA Biotechnology targets 2026 for FDA approval of cancer drug - Investing.com
Breakthrough Cancer Drug Pipeline: MAIA's Telomere-Targeting Therapy Eyes FDA Fast Track - Stock Titan
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - MSN
Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March? - Insider Monkey
MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025 - TipRanks
Q1 EPS Forecast for MAIA Biotechnology Lifted by Analyst - Defense World
MAIA Biotechnology revises offering to $11.2 million By Investing.com - Investing.com Australia
Diamond Equity Comments on MAIA Biotechnology Q1 Earnings - Defense World
MAIA Biotechnology revises offering to $11.2 million - Investing.com
Maia Biotechnology IncDecreases Maximum Aggregate Offering Price To $11.2 MillionSEC Filing - Marketscreener.com
15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - BioSpace
Breakthrough Lung Cancer Drug Shows Exceptional Phase 2 Results: Key Biomarker Discovery - Stock Titan
Maia Bio touts two advances for its lead cancer drug in development - Crain's Chicago Business
MAIA Biotechnology reports breakthrough in cancer treatment research By Investing.com - Investing.com South Africa
MAIA Biotechnology advances with new drug name approval By Investing.com - Investing.com Australia
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - BioSpace
MAIA Biotechnology reports breakthrough in cancer treatment research - Investing.com
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO - BioSpace
Maia Biotechnology Receives Usan Council Approval For "Ateganosine" As Nonproprietary Name For Anticancer Agent Thio - Marketscreener.com
MAIA Biotechnology advances with new drug name approval - Investing.com
MAIA Biotechnology receives USAN Council approval for ‘Ateganosine’ name - TipRanks
MAIA Biotechnology, Inc. Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO - Marketscreener.com
Major Milestone: MAIA's Novel Lung Cancer Drug Gets Official Name Ateganosine - Stock Titan
MAIA Biotechnology (MAIA) Expected to Announce Earnings on Thursday - Defense World
Maia Biotechnology director Guerrero Ramiro buys $49,999 in stock - Investing.com
MAIA Biotechnology, Inc. to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - Marketscreener.com
Maia Biotechnology Plans to Begin Phase 3 Lung Cancer Trial of THIO-104 in H2 -February 27, 2025 at 10:58 am EST - Marketscreener.com
MAIA Biotechnology to initiate THIO-104 trial - TipRanks
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - Business Wire
MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - Stock Titan
0.39%
3.66%
자본화:
|
볼륨(24시간):